Activin and Inhibin

DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC 50 of 0.396 nM for human DHODHIn VitroDHODH-IN-16 (Example 22) potently inhibits the growth of MOLM-13 cells with an IC 50 of 0.2 nM. MCE has not independently

DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC 50 of 0.396 nM for human DHODHIn VitroDHODH-IN-16 (Example 22) potently inhibits the growth of MOLM-13 cells with an IC 50 of 0.2 nM. MCE has not independently

DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC 50 of 0.396 nM for human DHODHIn VitroDHODH-IN-16 (Example 22) potently inhibits the growth of MOLM-13 cells with an IC 50 of 0.2 nM. MCE has not independently

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor ( IC 50 =0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML)In VitroDHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor with an IC 50

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor ( IC 50 =0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML)In VitroDHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor with an IC 50

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor ( IC 50 =0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML)In VitroDHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor with an IC 50

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor ( IC 50 =0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML)In VitroDHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor with an IC 50

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.In VitroDHODH-IN-23 (Compound A: 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM: 72 h) induces CDllb

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.In VitroDHODH-IN-23 (Compound A: 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM: 72 h) induces CDllb

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.In VitroDHODH-IN-23 (Compound A: 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM: 72 h) induces CDllb

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.In VitroDHODH-IN-23 (Compound A: 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM: 72 h) induces CDllb

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.In VitroDHODH-IN-23 (Compound A: 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM: 72 h) induces CDllb